- AI in respiratory diseases, encompassing advanced tools for imaging, diagnostics, and clinical decision support, is becoming an essential component of modern respiratory care across hospitals, diagnostic centers, and research institutions due to its ability to enhance diagnostic precision, predict disease progression, and support personalized treatment strategies
- The accelerating demand for AI in this field is primarily fueled by the rising global burden of chronic respiratory illnesses such as COPD and pulmonary infections, growing need for early and accurate detection, and increasing integration of AI in medical imaging and digital health platforms
- North America dominated the AI in respiratory diseases market with the largest revenue share of 45.1% in 2024, attributed to its advanced healthcare infrastructure, widespread use of digital health technologies, and robust investments in AI research, particularly across the U.S., where healthcare providers are increasingly adopting AI-driven imaging tools and predictive models
- Asia-Pacific is expected to be the fastest growing region during the forecast period, driven by improving healthcare access, rising healthcare expenditures, and government support for AI integration in clinical settings
- The CT scan segment dominated the AI in respiratory diseases market with a market share of 31.6% in 2024, owing to its central role in detecting and monitoring respiratory conditions, and the integration of AI algorithms for image analysis, disease quantification, and diagnostic support
